The considerations that manufacturers use in setting prices for curative treatments like gene therapy for sickle cell disease must go beyond a calculation of medical costs avoided and take into account factors such as existing co-morbidities, Sen. Bill Cassidy, R-La., advised at a policy conference in Washington DC Feb. 12.
Such an exercise would be crucial to establishing a “reasonable opening cost” for treatment, he told the conference, which was...






